<div>
  <ul>
    <li>
      <p>
        Ohio-based biotechnology company PsyBio Therapeutics plans to raise CAD 1 million in a private placement consisting of 20 million units priced at CAD 0.05 per unit. Each unit will consist of a share and a warrant that can be exercised to purchase one share at CAD 0.10 per share within two years. The first tranche is expected to close on or before December 23, 2022, subject to regulatory approvals
      </p>
    </li>
    <li>
      <p>
        The new funds will be used towards its ​​current good manufacturing practices (GMP) manufacturing, advancing clinical trials, and for working capital expenses.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.psychedelicfinance.com/articles/psybio-therapeutics-announces-non-brokered-private-placement-financing">
      Psychedelic Finance
    </a>
    &nbsp;
  </p>
</div>


Psychedelic Medicine

PsyBio Therapeutics plans CAD 1 million in private placement

PsyBio Therapeutics provides business update for Q3 2022; plans to expand patent portfolio to 29 in Q4

All Updates

PsyBio Therapeutics plans CAD 1 million in private placement

PsyBio Therapeutics provides business update for Q3 2022; plans to expand patent portfolio to 29 in Q4

PsyBio Therapeutics expands patent portfolio to 21 in Q2

PsyBio Therapeutics provides clinical update for Q1 2022

PsyBio Therapeutics’ earnings significantly improve by 45% in Q3 2021

PsyBio Therapeutics releases Q2 2021 financial results

PsyBio Therapeutics commences trading on OTCQB venture market